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Background: The hepatitis A virus (HAV) is the most frequent cause of viral hepatitis worldwide and is recognized
as one of the most widespread foodborne pathogens. HAV genotypes and subtypes differ in their geographic
distribution and the incidence of HAV infection varies considerably among countries, and is particularly high in
areas with poor sanitation and hygiene. Phylogenetic analyses are traditionally used in clinical microbiology for
tracing the geographic origin of HAV strains. In food microbiology, this approach is complicated by the low
contamination levels of food samples. To date, real-time reverse-transcription PCR has been one of the most
promising detection methods due to its sensitivity, specificity and ability to deliver quantitative data in food
samples, but it does not provide HAV subtyping information.
Results: Six subtype-specific RT-qPCR assays were developed for human HAV. The limit of detection of HAV was
50 genome copies/assay for subtype IIB, 500 genome copies assay for IA, IB, IIA and IIIB and 5000 genome
copies/assay for IIIA. The specificity of the assays was evaluated by testing reference isolates and in vitro HAV RNA
transcripts. No significant cross reactivity was observed. Subtyping results concordant with sequencing analysis were
obtained from 34/35 clinical samples. Co-infection with a minor strain of a different subtype was suggested in 5
cases and a recombinant event in one case.
Conclusions: These RT-qPCR assays may be particularly useful for accurately tracing HAV in low-level contaminated
samples such as food matrices but also to allow co-infection identification in human samples.
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Hepatitis A virus (HAV) is a small, non-enveloped hepato-
tropic virus classified into the Hepatovirus genus within
the Picornaviridae family. Its genome consists of an ap-
proximately 7.5 kilobase positive single-strand RNA com-
prising a 5’ untranslated region (5’UTR), a single open
reading frame (ORF) that encodes both structural and
non-structural proteins, and a 3’ UTR with a short poly
(A) tail. There is only one serotype of HAV. Genomic
characterization of HAV has been carried out mainly by
sequencing of strains from different geographic regions of
the world. Firstly, using a short fragment of the VP1/2A
junction region, strains were classified in to seven geno-
types on the basis of >15% nucleotide variation between* Correspondence: sylvie.perelle@anses.fr
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article, unless otherwise stated.isolates, and the subgenotypes with >7.5% to <15% nu-
cleotide variation [1]. Then, the complete genomic data
indicated that genotypes II and VII should be considered a
single genotype, based upon the complete VP1 sequence
[2; 3]. So, by sequencing of the VP1/2A junction and the
VP1 gene, three genotypes (I, II, III) divided in two sub-
types (A and B) have been described for humans and three
others (IV, V, VI) for primates [1-3].
HAV infection is the leading worldwide cause of acute
viral hepatitis [4,5]. There are an annual estimated of 1.5
million cases of hepatitis A worldwide [6]. Optimal use
of vaccination can significantly reduce the hepatitis A dis-
ease burden and the World Health Organization position
on hepatitis A vaccines depend on the level of endemicity
in countries. In highly endemic countries, large-scale vac-
cination programmes are not recommended. In countries
of intermediate endemicity, large-scale childhood vac-
cination may be considered as a supplement to healthd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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low endemicity, vaccination against hepatitis A is indi-
cated for individuals with increased risk of contracting
the infection such as travelers to areas of intermediate
or high endemicity [7]. HAV’s geographical distribution
is dependent on socioeconomic development and sani-
tation levels. In areas with high and very high endem-
icity (Africa, Middle East, India, Central and South
America), where infections are mostly asymptomatic
and epidemics are rare, 50% seroprevalence is reached
between the ages of 5 and 14 [8]. In areas with moderate
endemicity (Eastern Europe and south-eastern Asia),
50% seroprevalence is reached between the ages of 14 and
34 and epidemics can occur within the general population.
In areas with low endemicity (North America, Western
Europe and Australia), most of the population is still sus-
ceptible to HAV, particularly people over 50 years old, and
the risk of fulminant hepatitis is higher.
HAV is transmitted mainly by the fecal-oral route,
either by person-to-person contact or by ingestion of
contaminated water and food, particularly shellfish, soft
fruits and raw vegetables [9-16]. HAV is stable in the en-
vironment and is particularly resistant to disinfectants,
heating, pressure and low pH [4,17]. Contamination may
occur during growth in the field as well as during process-
ing, storage, distribution or final preparation. In developed
countries, low incidence and low vaccine coverage have
led to a high proportion of susceptible individuals, which
creates a potential for expanded hepatitis A outbreaks
when contaminated products are widely distributed [8].
The development of sensitive, reliable techniques for
the detection of HAV in food and water samples contrib-
utes to the safety of these products [18]. However, detec-
tion of HAV on the basis of its infectivity is complicated
by the absence of a reliable cell culture method and the
low contamination levels of food samples. HAV detection
is currently based on nucleic acid testing methods. The
International Organization for Standardization/Technical
specification (ISO/TS) 15216 standard was published in
the first half of 2013 and will be published as ISO stand-
ard methods after validation. These protocols target the
5’UTR which shows the lowest diversity across HAV ge-
notypes [19-22]. Currently, HAV genotyping relies on
amplification, sequencing and phylogenetic analysis of a
portion of the viral genome. However, these techniques
are time-consuming and may lack sensitivity, particularly
with food samples, where the level of contamination by
enteric viruses is often very low. Alternative approaches
for HAV genotyping in complex samples (food, environ-
mental) may help to better manage the risk. Indeed,
although genotypes I and III are the most frequently re-
ported worldwide, HAV genotypes and HAV strains differ
in their geographic distribution [23,24]; strain genotyping
can thus give clues to understanding food contaminationroutes. Currently, very few studies describe alternatives to
sequencing for HAV genotyping. In recent years single-
nucleotide polymorphism (SNP) genotyping has become
an area of intense investigation and a valuable tool for
diagnosing various pathologies. Various methods for SNP
detection have been reported including real-time PCR
performed with primers and a probe spanning the SNP
site [25].
The aim of this study was to develop a new approach
for the subgenotyping of human HAV based on six sim-
plex SNP genotyping RT-qPCR assays and to apply this
approach to human clinical samples.
Results
Design of HAV subtype RT-qPCR assays
The HAV subtype RT-qPCR assays were designed to give
subtype-specific amplification on the basis of SNP differ-
entiating the targeted subtype from the others. In other
words, at the SNP position, the same nucleotide was
found for all the subtypes except for the subtype of
targeted HAV. Consequently, different regions of HAV
genome were chosen given their subtype specificity and
the absence of major nonspecific homologies on BLAST
analysis. Moreover, degenerated bases were used to detect
genetic variation within a given subtype (Table 1; Table 2;
Figure 1).
Sensitivity of subtype-specific RT-qPCR assays
The sensitivity of the simplex subtype–specific RT-qPCR
assays was evaluated with serial 10-fold dilutions of
in vitro transcribed RNA for HAV IIA, IIB, IIIA and IIIB
and genomic RNA for HAV IA and IB. From 5 × 105 to
5 genome copies/assay for IA, IB, IIA, IIB, and IIIB and
from 5 × 107 to 5 × 102 genome copies/assay for IIIA were
tested. As shown on Table 3, mean RT-qPCR efficiency,
derived from the slope parameters, ranged from 83.9% for
IIIA to 109% for IB. R2 values were ≥0.898. The limit of
detection (LOD) obtained for IA, IB, IIA and IIIB was 500
genome copies/assay, whereas the LOD of IIB was 50 gen-
ome copies/assay and the LOD of IIIA was 5000 genome
copies/assay. The LOD of the consensus RT-qPCR assay
[19] was in the same range as that of the subtyping RT-
qPCR assays at 500 genome copies/assay.
Specificity of subtype-specific RT-qPCR assays
The specificity of the RT-qPCR assays was assessed by
testing HAV RNA of each subtype at a concentration of
5 × 104 genome copies/assay with all the subtype-specific
RT-qPCR assays. As shown on Table 4, detection of the
specific target was observed for all assays with Ct values
comprised between 25 and 37, consistent with assay sensi-
tivity. All but one were entirely specific. The IIA-specific
assay occasionally allowed amplification of the IIB target.
However, this non-specific IIB amplification was not
Table 1 GenBank accession numbers for HAV isolates
Genotype Reference strain GenBank accession number
HAV IA AB020564.1 EU526088; EU526089; EU131373; AB020567; X75216; EF406357; AB623053; X83302; X75214; AB020569;
AB618531; AB020565; K02990; AB618529; AF485328; EF207320; HM769724; AB020564; EU251188; X75215;
AB020568; HQ437707; AF512536; AB020566; AF357222
HAV IB M14707 HQ246217; NC_001489; M14707; HV192265; FB746524; M59810; EF406361; EF406359; EF405360; DQ646426;
EF406363; EF406362; AF268396; M59809; M16632; M59808; EF406358; AF314208; M20273
HAV IIA AY644676.1 AY574059; AY644676; GU390574; GU390572; GU390577; GU390576
HAV IIB AY644670.1 AY644670; Z77248; Z77247; Z77245; Z77244; Z77243; Z77246
HAV IIIA AB279732.1 AB279732; FJ360735; EU011791; FJ360730; FJ360733; DQ991030; AB279734; DQ991029; FJ360732;
FJ360734; AB279733; FJ360731
HAV IIIB AB279735.1 AB279735; AB258387; AB425339; AB300205
Nucleic acid sequences were used to design primers and probes sets.
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of IIB RNA was tested in the presence of a low concentra-
tion of the specific IIA target (50 genome copies/assay)
(data not shown).
Fecal and serum samples analysis
Human clinical fecal and serum samples were genotyped
by sequencing the VP1/2A region, as described [26] and
provided by the NRC. Then, they were tested with the
consensus RT-qPCR assay [19] and with all the subtype-
specific RT-qPCR assays separately (Tables 5 and 6).Table 2 Sequences of primers and probes in the direction 5’-3
Genotype Reference strain
HAV IA AB020564.1 Forward primer
Reverse primer
Probe
HAV IB M14707 Forward primer
Reverse primer
Probe
HAV IIA AY644676.1 Forward primer
Reverse primer
Probe
HAV IIB AY644670.1 Forward primer
Reverse primer
Probe
HAV IIIA AB279732.1 Forward primer
Reverse primer
Probe
HAV IIIB AB279735.1 Forward primer
Reverse primer
Probe
HAV 5’UTR M14707 Forward primer*
Reverse primer*
Probe*
The specific genotype SNP is in bold. Probes are FAM-BHQ except HAV 5’UTR whichFour of the five stool samples and 24 out of the 30
sera were detected by a single subtype-specific assay that
provided a subtype result consistent with VP1/2A sequen-
cing. The consensus and specific RT-qPCR assays gave
similar results with differences of quantification that
did not exceed 1.9 log10 (genome copies/μL or genome
copies/g).
In stool sample 1181216151 provided as a IA subtype
by the NRC, subtype-specific assays detected both IA
and IIA RNA, with a IIA concentration 5.2 log10 lower
than that of the IA subtype (Table 5). Similarly, in the 5’
Sequence Position
GCA TTT AGG TTT TTC CTC ATT 702-722
TCA ACK GAC TGA ATC ATT 837-820
TCC AAA CAA GGA ATT TTC CAG AC 743-765
AAG CTT ATT GTG TAY TGT TAT 2070-2090
CAG AAT CAT CTC CAA CYT 2223-2208
TTC TCC TTC TAA CGT TGC TTC CCA 2103-2125
ACY ATG ATG AGC AGA ATT G 2978-2996
GCA TAT TTT AAT CTC TGC TT 3129-3110
AGA CCT GGA ATC GTC AGT GGA TGA 3004-3027
GGA GAT TTG AAA GTC ATA TTG 3047-3067
TTC CTG GGC ATA CTT TAG 3135-3118
AGT CTT AAT TCT TTG TAT GGT TTTC 3078-3094
TCC CTT GGA TTT GAC AAT 2605-2622
RGT ATT RAA CCT AAC AGC 2763-2747
AAT TAT AAC TGG GGC TAC TGA TGT T 2623-2647
AAT CCG ATG CTT CTC AAG 1560-1577
GCC TTC CTG AAT GGT ATT 1841-1824
AAA ATT ACA CAC TTY ACA ACY TGG A 1589-1613
TCA CCG CCG TTT GCC TAG 68-85
GGA GAG CCC TGG AAG AAA G 241-223
CCT GAA CCT GCA GGA ATT AA 169-150
is FAM-MGB. *: Costafreda et al. [19].
Figure 1 HAV genome regions targeted for genotyping. The different genomic regions used to identify each HAV genotype are represented
below the HAV genome scheme.
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specific assays detected both IA and IB RNA, with IB
concentrations 0.7 to 2 log10 lower than IA. A single dis-
crepant result was observed for serum sample 1311062298
provided as a IB subtype by VP1/ 2A region sequencing
and identified as a IA subtype by the subtype-specific RT-
qPCR assays (Table 6).
In conclusion, the subgenotyping RT-qPCR assays
allowed detecting 100% (35/35) of the clinical samples
for the presence of HAV. In total, 80.0% (28 samples) of
the clinical samples were found to correlate with the
genotyping by sequencing the VP1/2A region. Further-
more, positivity for more than one genotype identified
by sequencing appeared in 17.1% (6 samples) of the clin-
ical samples and a subtype discrepancy in 2.9% (1 sam-
ple) of the clinical samples.
Discussion
Although HAV has been shown to possess a single




Mean Ct values +/− SD
HAV IA HAV IB HAV IIA
5 x 107 / / /
5 x 106 / / /
5 x 105 26.28 ± 0.59 26.54 ± 0.95 26.64 ± 0.60
5 x 104 30.01 ± 0.58 29.60 ± 0115 30.26 ± 0.52
5 x 103 33.34 ± 0.66 32.66 ± 1.47 33.82 ± 0.56
5 x 102 36.28 ± 0.69 36.16 ± 1.48 36.59 ± 0.79
5 x 101 nd nd nd
5 x 100 nd nd nd
E 99.0% 109.0% 95.8%
R2 0.974 0.898 0.973
Parameters of RT-qPCR amplification curves obtained for HAV detection by the RT-q
of detection (LOD) has been defined as the lowest amount of HAV detected in thesingle serotype, HAV strains isolated from different parts
of the world have been classified into six genotypes (I to
VI), of which genotype I, II, and III can infect humans.
Genotype I is the most prevalent worldwide, and subtype
IA is more common than IB. The other human geno-
types are infrequent. In areas of low endemicity such as
the United States and Western Europe, IA dominates but
all genotypes and subtypes have been reported [23,28,29].
Genotype II isolates were originally identified in France in
1979 and Sierra Leone in 1988 [1] and appear to be lim-
ited to West Africa [30]. Genotype III has been reported
in many parts of the world [28] but is prevalent in the In-
dian subcontinent. An increase in genotype IIIA infections
has been reported in Korea, Russia, Estonia and in Japan.
Moreover, IIIA and IIIB co-circulate broadly with IA and
IB strains [5].
Phylogenetic analysis is useful to trace back the geo-
graphical origin of a given strain and for tracking transmis-
sions of HAV. Accurate typing of HAV from food samples
could thus be helpful for transmission investigations.HAV IIB HAV IIIA HAV IIIB HAV 5'UTR
/ 26,56 ± 0,89 / /
/ 29,49 ± 0,88 / /
22.25 ± 0.45 32.97 ± 0.94 24.50 ± 0.50 27.07 ± 1.00
25.53 ± 0.35 36.90 ± 1.69 27.65 ± 0.48 30.76 ± 0.74
28.62 ± 0.66 41.34 ± 0.69 31.58 ± 0.47 33.32 ± 0.79
32.00 ± 0.67 nd 35.64 ± 1.48 37.16 ± 1.83
35.79 ± 1.09 / nd nd
nd / nd nd
100.8% 83.9% 86.5% 102.2%
0.982 0.952 0.966 0.916
PCR reference method and HAV subgenotyping by RT-qPCR assays. The limit
three experiments and is shown in bold. nd: not detected. / : not analyzed.
Table 4 Specificity of subgenotyping RT-qPCR assays
Set primers/probe
HAV IA HAV IB HAV IIA HAV IIB HAV IIIA HAV IIIB
Sample HAV IA 30.01 ± 0.58 (6/6) - - - - -
HAV IB - 29.60 ± 1.15 (6/6) - - - -
HAV IIA - - 30.57 ± 0.87 (6/6) - - -
HAV IIB - - 35.02 ± 1.31 (4/6) 25.53 ± 0.35 (6/6) - -
HAV IIIA - - - - 36.90 ± 1.69 (6/6) -
HAV IIIB - - - - - 27.65 ± 0.48 (6/6)
Six subtyping RT-qPCR assays were tested with 5 x 104 genome copies/assay for all subtypes of HAV in duplicate in three different experiments. Results are
expressed as means cycle threshold (Ct) values ± standard deviations (SD). The number of positive Ct values is given in parentheses.
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sequencing approach is often impaired by the low contam-
ination levels, and does not give access to potential con-
tamination by several strains. Indeed, implicated items
(such as seafood, fruits and salads) in foodborne outbreaks
can harbour a heterogeneous HAV population that reflects
the diversity of the viral strains circulating at the geo-
graphic location of item contamination [31].
Two commercial quantitative HAV RT-qPCR assays
have been described. The detection limit was 2 TCID50
/mL for the Roche kit and 5 TCID50/mL for the Artus
kit. Both kits have been found suitable for detection and
quantification of HAV but only the Roche kit allowed the
differentiation between genotype IA and IB after melting
curve analysis [32]. The present study introduces six RT-
qPCR-based assays for specific molecular genotyping of
hepatitis A virus. To our knowledge, this is the first time
that HAV subtyping has been achieved by specific qPCR
probes. This subtype identification method can be imple-
mented in diagnostic and research laboratories, avoiding
post-PCR analysis and avoiding the problem of low viral
loads in food samples.
All subtype assays were found suitable for quantification
measurement for comparison with the data obtained with
the reference RT-qPCR assay (detecting all genotypes).
The minimal variations (around 1log10) observed for the
quantification were potentially due to the differences in
amplification efficiencies and calibration curves used.
Most of the samples were correctly identified with regard
to the genotype provided by VP1/2A sequencing. In 6
samples (1 stool and 5 sera), the specific RT-qPCR assay
identified a major IA strain, the same one determined by
VP1/2A sequencing, also in addition to a second subtype,
present in a lower concentration.
The conventional genotyping used as a reference assay
is a “golden standard assay”. The design of HAV subgeno-
typing RT-qPCR assays was based on SNP in the probe as-
sociated with degenerated bases in the primers to enhance
the specificity. Nevertheless, cross-reactivity could be only
definitively excluded with the entire genome sequencing
for the tested samples. However, co-circulation of thesubgenotypes IA and IIIA has been reported in India [33]
and of IA, IB and IIIA in Korea [34]. Co-circulation of the
subgenotypes IA and IB in South Africa, South America,
Europe and the US and the existence of recombination
events between subgenotypes have also been observed
[35-37]. Indeed, HAV exploits all known mechanisms of
genetic variation to ensure its survival, including mutation
and recombination [38,39]. HAV recombination was ori-
ginally reported in cell culture [40]. Its extent in nature
was appreciated only recently [35,36,38,39,41] and it ap-
pears that recombination occurs along the entire length of
the genome [38].
The present finding from the stool sample of a patient
who had not traveled abroad may be due to a co-infection
by IA and IIA subtypes. Indeed, HAV IA is the dominant
strain in France but IIA strains have been isolated among
French travelers returning from Africa as well as from
autochthonous cases [30]. A co-infection rather than an
event of recombination is suggested because of the huge
difference in the concentration of the subtypes. Regarding
these two signals, although non-specific amplification due
to a very high viral load cannot be excluded, it should be
noted that no IIA amplification was detected from any of
the 14 HAV IA serum samples.
The discovery of a major IA signal, combined with a
10- to 100-fold lower IB signal in 5 sera from patients
having traveled abroad (at least for three of them) may
suggest either an event of recombination or, more likely,
a co-infection. For these samples, the genome copy num-
bers determined by the 5’-UTR assay was not the sum of
those determined by subgenotyping RT-qPCR assays to-
gether which can be explained by the lack of accurate
quantification or by cross reactivity. As conventional
Sanger sequencing does not allow accurate identification
of multiple species within a sample, the hypotheses could
be investigated by cloning and sequencing or by next gen-
eration sequencing.
A single sample from a patient contaminated in Morocco
provided a discrepant result by specific RT-qPCR and
sequencing; this sample may correspond to an IA/IB re-
combinant in the P1 region of the HAV genome since IA-
Table 5 Stool samples analysis
Stool Age/Sex Transaminases IU/mL Travel Genotype by
sequencing












5’UTR IA IB IIA IIB IIIA IIIB
0780627147 21-30/M NC none IA 2.30 x107 1.93 x108 - - - - - IA : −0.92 -
1280210015 51-60/F 5680 Senegal IB 1.50 x1010 - 7.19 x1010 - - - - IB : −0.68 -
1280514230 51-60/F 7191 Benin IB 6.85 x1010 - 6.37 x1010 - - - - IB : +0.03 -
1181216151 51-60/F 3623 none IA 7.75 x1011 5.75 x1011 - 3.85 x106 - - - IA : +0.13 ; IIA : +5.30 −5.17
078014121 51-60/F NC Morocco IB 1.12 x107 - 3.73 x105 - - - - IB : +1.48 -
Each sample was tested with the reference RT-qPCR assay targeting the 5’UTR of HAV and the 6 genotype-specific RT-qPCR assays. The subtyping results were compared with those obtained with sequencing by the
NRC. Concentrations are given in genome copies per gram of stool. NC = Not communicated. The difference of quantification between 5’UTR and subtype RT-qPCR assays is calculated by the formula: (log10 (genomes
copies determined by reference RT-qPCR/genomes copies determined by subgenotyping RT-qPCR assays)). The difference of quantification between IA and IIA subtypes by RT-qPCR assays is calculated by the formula:




















Table 6 Serum samples analysis
Serum Age/Sex Transaminases IU/mL Travel Genotype by
sequencing










5’UTR IA IB IIA IIB IIIA IIIB
1310074855 61-70/F 3935 Ethiopia IB 1.50 x108 - 2.87 x108 - - - - IB : −0.28 -
1310016965 11-20/M 400 NC IB 3.13 x105 - 4.18 x103 - - - - IB : +1.87 -
1311012387 1-10/F NC NC IA 6.37 x104 9.26 x104 - - - - - IA : −0.16 -
1311018436 1-10/M NC NC IA 2.86 x104 3.60 x104 - - - - - IA : −0.10 -
1311072234 31-40/F 2018 NC IA 7.36 x104 7.31 x104 8.58 x103 - - - - IA : 0 ; IB : +0.93 −0.93
1310064958 61-70/M 2314 Guadeloupe IA 4.73 x105 5.50 x105 - - - - - IA : −0.07 -
1311009716 51-60/M 2339 NC IB 1.70 x106 - 2.30 x106 - - - - IB : −0.13 -
1311071503 1-10/M 358 NC IA 2.72 x105 2.85 x106 3.22 x104 - - - - IA : −1.02 ; IB : +0.93 −1.95
1310024892 1-10/M NC Morocco IA 6.14 x106 6.47 x106 - - - - - IA : −0.02 -
1310066012 1-10/F 1113 Morocco IA 2.04 x103 2.48 x103 - - - - - IA : −0.09 -
1309036458 11-20/M 3393 Cameroun IIA 3.42 x105 - - 4.66 x106 - - - IIA : −1.13 -
1309064503 1-10/F 2470 Algeria IA 3.27 x103 3.99 x103 - - - - - IA : −0.09 -
1309044888 11-20/M 1352 Guinea IB 4.10 x105 - 7.00 x105 - - - - IB : −0.23 -
1310077770 31-40/M NC Ethiopia IB 1.48 x106 - 4.35 x106 - - - - IB : −0.47 -
1310044717 51-60/F 6500 NC IB 7.16 x105 - 1.32 x106 - - - - IB : −0.26 -
1311011402 1-10/M 993 Ethiopia IB 7.89 x105 - 1.38 x106 - - - - IB : −0.24 -
1311018712 41-50/M NC Ethiopia IB 4.63 x103 - 1.22 x104 - - - - IB : −0.42 -
1310005428 21-30/M 3400 Morocco IA 5.87 x103 1.52 x104 1.37 x102 - - - - IA : −0.41 ; IB : +1.63 −2.05
1311011353 41-50/F 1736 Ethiopie IB 4.43 x104 - 9.28 x104 - - - - IB : −0.32 -
1310023611 21-30/F 1388 Tunisia IA 3.84 x104 2.09 x104 4.57 x103 - - - - IA : +0.26 ; IB : +0.92 −0.66
1380219001 51-60/M 4000 Madagascar IIIA 4.73 x105 - - - - 3.10 x104 - IIIA : +1.18 -
1311018504 61-70/F 1334 NC IB 6.96 x104 - 2.09 x105 - - - - IB : −0.48 -
1309047363 11-20/F 2000 NC IB 9.76 x104 - 1.30 x105 - - - - IB : −0.12 -
1310011213 1-10/M 1831 Algeria IA 7.89 x104 6.68 x104 4.77 x103 - - - - IA : +0.07 ; IB : +1.22 −1.15
1309064723 11-20/F 1494 Morocco IA 3.22 x104 2.76 x104 - - - - - IA : +0.07 -
1309039311 1-10/M NC Guinea IB 1.25 x105 - 5.35 x105 - - - - IB : −0.63 -




















Table 6 Serum samples analysis (Continued)
1310078280 1-10/F 857 Tunisia IA 6.06 x104 3.41 x104 - - - - - IA : +0.25 -
1380311211 61-70/M 1269 Madagascar IIIA 1.48 x104 - - - - 4.25 x104 IIIA : −0.46 -
1311062298 11-20/F 940 Morocco IB 2.95 x102 2.64 x102 - - - - - IA : +0.05 -
Each sample was tested with the reference RT-qPCR assay targeting the 5’UTR of HAV and the 6 genotype-specific assays. The subtyping results were compared with those obtained with sequencing by the NRC.
Concentrations are given in genome copies per μl of serum. NC = Not communicated. The difference of quantification between 5’UTR and subtype RT-qPCR assays is calculated by the formula: (log10 (genomes copies
determined by reference RT-qPCR/genomes copies determined by subgenotyping RT-qPCR assays)). The difference of quantification between IA and IB subtypes by RT-qPCR assays is calculated by the formula: (log10
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820) and sequencing targets the VP1/2A region (nt 2870
to 3381). The sequencing of this sample was attempted
but has been unsuccessful may be because of the low
viral load.
Conclusions
It was concluded that the RT-qPCR assays developed in
this study are suitable tools for quantification of HAV
and subtype identification. They need to be validated by
testing a larger number of clinical, environmental and
food samples. Conventional genotyping used as a refer-
ence assay is a “golden standard assay”, and the RT-qPCR
assays described here could be recommended as an add-
itional test to the conventional genotyping and for use in
cases of failure of the conventional typing method. They
may be particularly useful for accurately tracing HAV in
samples with low-level contamination such as food
matrices, but also can provide easy identification of a
co-infection in human samples.
Methods
Viral isolates
The genotype IB HM175/18f strain, clone B (VR-1402)
was obtained from the American Type Culture Collection
(ATCC). This clone replicates rapidly and has cytopathic
effects in cell culture [40]. HAV stock was produced by
propagation in foetal rhesus monkey kidney (FRhK-4) cells
(ATCC, CRL-1688) [42] and titrated by plaque assay [43].
Results were expressed in plaque-forming units/mL (PFU/
mL) and HAV stock contained 107 PFU/mL. Aliquots of
100 μL were kept frozen at −80°C for later use.
Clinical samples
Ethics statement: Hepatitis A virus infection is a notifi-
able disease in France. The current system of mandatory
reporting was approved by the Commission Nationale
de l’Informatique et des Libertés (deliberation n° 02–082,
November 19 2002). Patients receive oral and written infor-
mation on the finality of the notification and on the modal-
ities of information recording. This information is available
on line on the web site of the Institut de Veille Sanitaire
(IVS) at http://www.invs.sante.fr/content/download/6498/
42945/version/2/file/fiche_info_patient.pdf.
All clinical and biological parameters are treated an-
onymously. The virological surveillance of strain diversity
is performed on stored samples obtained for hepatitis A
diagnosis (no need for any additional blood draw). Diag-
nostic laboratories are asked to contribute to HAV strains
surveillance by sending samples to the National Reference
Centre (NRC) for HAV. All data and samples are an-
onymously collected and analyzed. The study was con-
ducted in accordance with the ethics principles of the
Declaration of Helsinki.HAV genotyping from stools and serum samples col-
lected by the French NRC for Hepatitis A was deter-
mined by sequencing of the VP1/2A junction region as
previously described [26]. Stool samples were suspended
in 10 mM Phosphate Buffered Saline (PBS), pH 7.4, to
obtain a final 10% suspension (w/v), vortexed and centri-
fuged at 3000 g for 30 min at 4°C. Aliquots of 100 μL
supernatant were kept frozen at −80°C for later use.
Serum samples were kept frozen at −80°C until later use.
Viral RNA extraction
Aliquots of frozen fecal samples or viral stocks were
supplemented with NucliSens® easyMAG™ lysis buffer
(BioMérieux, Marcy l’Etoile, France) up to 3 mL and sub-
jected to the NucliSens® easyMAG™ platform (Biomérieux)
for total nucleic acid extraction by the “off board Specific
A protocol” according to manufacturer’s instructions. Nu-
cleic acids were finally eluted in 70 μL of elution buffer
and stored at −80°C.
Two hundred μL of frozen sera samples were subjected
to the NucliSens® easyMAG™ platform (Biomérieux) for
total nucleic acid extraction by the “Specific B protocol”
according to manufacturer’s instructions. Nucleic acids
were then eluted in 50 μL of elution buffer and stored
at −80°C.
HAV RNA in vitro transcripts
The cDNA corresponding to nucleotides 39–518 (5’UTR)
of the IB genomic sequence (M59808.1) was cloned into
the pGEM-T Easy vector (Promega, Charbonnières-les-
Bains, France) and propagated in E. coli One Shot®
TOP10F’ (Life technologies, Saint Aubin, France). High
quality DNA plasmid containing HAV regions (p-HAV5)
was purified using the Qiagen Plasmid midi kit (Qiagen,
Courtaboeuf, France) according to the manufacturer’s
protocol.
HAV cDNA of genotypes IIA, IIB, IIIA or IIIB corre-
sponding respectively to the 588–3183, 587–3183, 618–
3210 and 618–3210 positions of the genomic sequence
(AY644676.1, AY644670.1, AB279732.1, AB279735.1) were
cloned into the pBluescriptIISK + vector by Genecust
(Dudelange, Luxembourg). All recombinant plasmids were
purified by Genecust and used to produce RNA tran-
scripts. HAV IIA, IIB, and IIIB DNA plasmids (0,5 μg)
were digested with HindIII (Life technologies) and HAV
5’UTR and HAV IIIA DNA plasmids were digested with
SpeI (Life technologies). Digested plasmids were tran-
scribed by using the MEGAscript® kit (Life technologies)
according to the manufacturer’s protocol. Synthesized
RNA was treated twice with Turbo™ DNase (Life technolo-
gies) according to the manufacturer’s protocol in order to
remove the DNA template following transcription, and
purified by using the MEGAclear kit (Life technologies) ac-
cording to manufacturer’s instructions. The synthesized
Coudray-Meunier et al. BMC Microbiology 2014, 14:296 Page 10 of 11
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measuring absorbance at 260/280 nm with a Nanodrop
ND-100 (Thermoscientific, France) and the free software
available on the “http://endmemo.com/bio/dnacopynum.
php” website. RNA stocks were diluted to contain 109
copies/μL and aliquoted and stored at - 80°C.
Titers of the clarified fecal suspensions, serum samples
and HM175/18f supernatants were obtained by RT-qPCR
targeting the 5’UTR (see below), using a standard curve de-
rived from ten-fold dilutions of the 5’UTR transcript RNA
from p-HAV5. Titer was expressed in genome copies.
Primers and probes
The RT-qPCR assay targeting the 5’UTR described by
Costafreda et al. [19] was used to detect all HAV geno-
types. This RT-qPCR assay is referred to as “consensus
RT-qPCR”. Primers and probe sets were designed by using
Beacon Designer software (Bio-Rad, Marnes-la-Coquette,
France) to give subtype-specific amplification on the basis
of single nucleotide polymorphisms. To identify genotype-
specific conserved regions of HAV, complete sequences
available from GenBank (NCBI) were aligned (Table 1)
with MUSCLE software [44] and multiple alignment was
visualized with JALVIEW software (version 2.8) [45].
Hydrolysis probes were labeled at the 5’ end with 6-
carboxyfluorescein (FAM) and at the 3’ end with black
hole quencher 1 (BHQ1) (Table 2 and Figure 1).
Primers and probes were purchased from Life Tech-
nologies or Eurofins MWG Operon (Les Ulis, France).
RT-qPCR conditions
Quantitative one-step RT-PCR for detection of HAV was
carried out on a CFX96™ real-time PCR detection system
from Bio-Rad. Reactions were performed in a 15 μL
reaction mixture containing 1X of RNA UltraSense™
master mix and 0.63 μL of RNA Ultrasense™ enzyme mix,
which are components of RNA UltraSense™ One-Step
Quantitative RT-PCR System (Life technologies), 2 U
RNAse inhibitor (Life technologies), 5 μg of bovine serum
albumin (Life Technologies), 500 nM of forward primer,
900 nM of reverse primer, 250 nM of probe, and 5 μL of
sample. A negative control containing all the reagents ex-
cept the RNA template was included in each set of reac-
tions. The one-step RT-qPCR program involved 60 min
reverse transcription of RNA at 55°C, followed by a 5 min
denaturation step at 95°C, and finally 45 cycles of 15 s at
95°C, 1 min at 56°C and 1 min at 65°C. Fluorescence was
automatically recorded by the instrument at the end of
the elongation steps (1 minute at 65°C) for each amplifi-
cation cycle. All samples were characterized by a corre-
sponding cycle threshold (Ct) value. Negative samples
gave no Ct value. For each specific RT-qPCR assay, a
standard curve was generated using 10-fold dilutions of
titered RNA corresponding to each subtype. For theconsensus RT-qPCR assay, a standard curve was gener-
ated using 10-fold dilutions of titered RNA transcripts
from p-HAV5. The slopes (S) of the regression lines
were used to calculate the amplification efficiency (E) of
the RT-qPCR reactions, according to the formula E =10|-
1/s| -1 [46].
Assay performance assessment
Genotype IB HAV RNA obtained from HM175/18f, geno-
type IA RNA obtained from a fecal sample (stool number
128061099) and genotype IIA, IIIA, IIB, IIIB RNA tran-
scripts were used to determine the sensitivity and the spe-
cificity of the subgenotyping RT-qPCR assays. All samples
were analyzed in duplicate in three different experiments
resulting from 6 Ct values.
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